FDA-Approved Prostate Cancer Treatments

FDA-Approved Prostate Cancer Treatments FDA-Approved Prostate Cancer Treatments – MPR

FDA-APPROVED PROSTATE CANCER TREATMENTS
Generic	Brand	Strength	Form	Usual Dose
ALKYLATING AGENT
estra– mustine	Emcyt	140mg	caps	14mg/kg in 3 or 4 divided doses
ANTHRACENEDIONE
mitoxan– trone	—	2mg/mL	soln for IV infusion after dilution	12−14mg/m² every 21 days
ANTIANDROGENS
abiraterone acetate	Yonsa	125mg	tabs	CRPC: 500mg once daily (in combination with methylprednisolone 4mg twice daily). Give concurrent GnRH analog or should have had bilateral orchiectomy.
abiraterone acetate	Zytiga	250mg, 500mg	tabs	1g once daily on an empty stomach (in combination with oral prednisone 5mg twice daily [CRPC] or 5mg once daily [CSPC]). Give concomitant GnRH analog or should have had bilateral orchiectomy.
apalutamide	Erleada	60mg	tabs	240mg once daily. Give concurrent GnRH analog or should have had bilateral orchiectomy.
bicalu– tamide	Casodex	50mg	tabs	50mg daily
darolu– tamide	Nubeqa	300mg	tabs	CRPC: 600mg twice daily. Give concurrent GnRH analog or patient should have had bilateral orchiectomy.
enzalu– tamide	Xtandi	40mg	caps	CRPC, mCSPC: 160mg once daily. Give concurrent GnRH analog or should have had bilateral orchiectomy.
flutamide	—	125mg	caps	250mg every 8hrs
nilutamide	Nilandron	150mg	tabs	300mg once daily for 30days, then 150mg once daily, starting day of or day after surgical castration
ANTIMICROTUBULE AGENTS
docetaxel	Taxotere	20mg/mL	soln for IV infusion after dilution	75mg/m² once every 3wks
cabazitaxel	Jevtana	60mg/ 1.5mL	soln for IV infusion after dilution	25mg/m² once every 3wks with oral prednisone 10mg daily during treatment
AUTOLOGOUS CELLULAR IMMUNOTHERAPY
sipuleucel‑T	Provenge	Minimum 50 million autolo– gous CD54+ cells activated with PAP-GM-CSF/ 250mL dose	susp for IV infusion	Autologous use only. Obtain product release from manufacturer, match patient identity on product and Cell Product Disposition form, check expiration date and time on product before infusing. Premedicate 30min before infusion with acetaminophen and antihistamine. Give three doses at 2‑wk intervals. For each dose: Give entire contents of bag by IV infusion over 60min; do not use filter; do not use if clumps do not disperse with gentle mixing. Observe patient for at least 30min after infusion. May interrupt or slow infusion if acute transfusion reaction occurs; do not restart if product at room temp for >3hrs.
ESTROGENS*
conjugated estrogens	Premarin	0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg	tabs	1.25−2.5mg 3 times daily
estradiol	Estrace	0.5mg, 1mg, 2mg	scored tabs	1−2mg 3 times daily
estradiol valerate	Delestrogen	10mg/mL, 20mg/mL, 40mg/mL	soln for IM inj	30mg or more every 1 or 2wks
estrogens, esterified	Menest	0.3mg, 0.625mg, 1.25mg, 2.5mg	tabs	1.25−2.5mg 3 times daily
GnRH ANALOGUES
goserelin acetate	Zoladex	3.6mg	SC implant	Advanced prostate cancer: One 3.6mg implant every 28 days or one 10.8mg implant every 12wks. Stage B2-C prostatic carcinoma (in combination with flutamide): Initially one 3.6mg implant, followed in 28 days by one 10.8mg implant; or may use one 3.6mg implant every 28 days. Treat 8wks prior to and during radiotherapy.
goserelin acetate	Zoladex 3-Month 10.8mg	10.8mg	SC implant
histrelin acetate	Vantas	50mg	SC implant	Insert 1 implant SC in the inner aspect of the upper arm; remove or replace after 12mos
leuprolide acetate	—	5mg/mL	soln for SC inj	1mg SC daily
	Eligard	7.5mg, 22.5mg, 30mg, 45mg	ext-rel susp for SC inj	7.5mg SC once per month; or 22.5mg SC once every 3mos; or 30mg SC once every 4mos; or 45mg SC once every 6mos
	Lupron Depot 7.5mg	7.5mg	depot susp for IM inj	7.5mg IM once a month (4wks); or 22.5mg IM once every 3mos (12wks); or 30mg IM once every 4mos (16wks); or 45mg IM once every 6mos (24wks)
	Lupron Depot–3month 22.5mg	22.5mg
	Lupron Depot–4month 30mg	30mg
	Lupron Depot – 6month 45mg	45mg
triptorelin pamoate	Trelstar	3.75mg, 11.25mg, 22.5mg	pwd for IM inj after reconsti– tution	3.75mg every 4wks or 11.25mg every 12wks or 22.5mg every 24wks
GnRH ANTAGONIST
degarelix	Firmagon	80mg/ vial, 120mg/ vial	pwd for SC inj after reconsti– tution	Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days.
NOTES
KEY: CRPC = castration-resistant prostate cancer; CSPC = castration-sensitive prostate cancer; mCSPC = metastatic castration-sensitive prostate cancer *For palliative treatment only. Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling. (Rev. 4/2020)

Want to read more?